IMAGE: Seropositive (RF and/or anti-CCP) patients receiving rituximab had a higher DAS remission rate versus MTX alone than seronegative patients at Week 52
{"Image DocumentName": "IMAGE: Seropositive (RF and/or anti-CCP) patients receiving rituximab had a higher DAS remission rate versus MTX alone than seronegative patients at Week 52", "Image ImageDescription": "In the IMAGE study of patients with early RA, there was a greater difference in the proportion of patients achieving remission for patients seropositive for RF and/or anti-CCP receiving rituximab versus those receiving MTX alone than seronegative patients. n Mariette et al.,", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}